Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

Financials

In the last quarter, ArcticZymes had revenue of €3.02m and net profit of €125.29k
(EUR) September 2026
YoY
Revenue 3.02m 24.11%
Gross profit 2.81m 391.41%
Net profit 125.29k 55.45%
EBITDA 284.96k 5.35%

Fundamentals

Metric Value
Market capitalization
€104.14m
Number of shares
51.07m
52-week high/low
€2.51 - €1.73
Dividends No
Beta
0.60
P/E ratio
79.59
PEG ratio
0.64
P/B ratio
2.81
P/S ratio
8.44

Company profile

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, In vitro diagnostics, and biomanufacturing. It offers salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; shrimp alkaline phosphatase and derived kits for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of double stranded DNA; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining DNA /RNA fragments. It operates in Norway, Germany, Lithuania, Italy, other countries in Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was incorporated in 1990 and is headquartered in Tromsø, Norway.

Name
ArcticZymes
CEO
Michael Benjamin Akoh
Headquarters Tromsø, tr
Norway
Website
IPO
04/11/2005
Employees 54

Ticker symbols

Exchange Symbol
Osl
AZT.OL
Frankfurt
B4V.F
Düsseldorf
B4V.DU
London
0DRV.L
SIX
B4V.SW
München
B4V.MU
🍪

Parqet  uses cookies. Learn more